You are here

Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DE024024-01
Agency Tracking Number: R43DE024024
Amount: $199,997.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDCR
Solicitation Number: PA13-088
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
SALT LAKE CITY, UT 84108-1228
United States
DUNS: 827444345
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (507) 358-4465
Business Contact
Phone: (801) 649-3999
Research Institution

DESCRIPTION (provided by applicant): GlycoMira Therapeutics has developed safe and effective anti-inflammatory glycosaminoglycan derivatives and proposes to test the feasibility of using its lead compound to treat or prevent oral mucositis. Mucositis is acommon and debilitating complication of cancer treatment. Cancer patients undergoing radiation or chemotherapy often develop this painful inflammatory disease within a week of starting radio-chemotherapy. The clinical manifestations include ulcers in themouth and gastrointestinal tract, and are exacerbated by opportunistic infections by oral and pathogenic microorganisms. Many patients also suffer from dry mouth due to decreased salivary flow, with pain and difficulty in swallowing, often necessitating installation of a feeding tube. The severity of mucositis frequently results in interruptions to the cancer treatment, dose reductions and even unplanned emergency room visits and hospitalizations. In head and neck cancer treatments, where more than 80%

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government